260 related articles for article (PubMed ID: 20624866)
1. The cost-effectiveness of screening for colorectal cancer.
Telford JJ; Levy AR; Sambrook JC; Zou D; Enns RA
CMAJ; 2010 Sep; 182(12):1307-13. PubMed ID: 20624866
[TBL] [Abstract][Full Text] [Related]
2. The economic evaluation of screening for colorectal cancer: Case of Iran.
Barouni M; Ghaderi H; Shahmoradi MK
Clin Lab; 2013; 59(5-6):667-74. PubMed ID: 23865368
[TBL] [Abstract][Full Text] [Related]
3. Markov's modeling for screening strategies for colorectal cancer.
Barouni M; Larizadeh MH; Sabermahani A; Ghaderi H
Asian Pac J Cancer Prev; 2012; 13(10):5125-9. PubMed ID: 23244122
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of colonoscopy in screening for colorectal cancer.
Sonnenberg A; Delcò F; Inadomi JM
Ann Intern Med; 2000 Oct; 133(8):573-84. PubMed ID: 11033584
[TBL] [Abstract][Full Text] [Related]
5. Optimal use of colonoscopy and fecal immunochemical test for population-based colorectal cancer screening: a cost-effectiveness analysis using Japanese data.
Sekiguchi M; Igarashi A; Matsuda T; Matsumoto M; Sakamoto T; Nakajima T; Kakugawa Y; Yamamoto S; Saito H; Saito Y
Jpn J Clin Oncol; 2016 Feb; 46(2):116-25. PubMed ID: 26685321
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of screening for colorectal cancer in the general population.
Frazier AL; Colditz GA; Fuchs CS; Kuntz KM
JAMA; 2000 Oct; 284(15):1954-61. PubMed ID: 11035892
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness and budget impact analyses of colorectal cancer screenings in a low- and middle-income country: example from Thailand.
Phisalprapa P; Supakankunti S; Chaiyakunapruk N
J Med Econ; 2019 Dec; 22(12):1351-1361. PubMed ID: 31560247
[No Abstract] [Full Text] [Related]
8. Cost effectiveness and projected national impact of colorectal cancer screening in France.
Hassan C; Benamouzig R; Spada C; Ponchon T; Zullo A; Saurin JC; Costamagna G
Endoscopy; 2011 Sep; 43(9):780-93. PubMed ID: 21623557
[TBL] [Abstract][Full Text] [Related]
9. Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening.
Lansdorp-Vogelaar I; van Ballegooijen M; Zauber AG; Habbema JD; Kuipers EJ
J Natl Cancer Inst; 2009 Oct; 101(20):1412-22. PubMed ID: 19779203
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of colorectal cancer screening: comparison of community-based flexible sigmoidoscopy with fecal occult blood testing and colonoscopy.
O'Leary BA; Olynyk JK; Neville AM; Platell CF
J Gastroenterol Hepatol; 2004 Jan; 19(1):38-47. PubMed ID: 14675241
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of colorectal cancer screening with stool DNA testing in intermediate-incidence countries.
Wu GH; Wang YM; Yen AM; Wong JM; Lai HC; Warwick J; Chen TH
BMC Cancer; 2006 May; 6():136. PubMed ID: 16723013
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of colorectal cancer screening using colonoscopy, fecal immunochemical test, and risk score.
Sekiguchi M; Igarashi A; Sakamoto T; Saito Y; Esaki M; Matsuda T
J Gastroenterol Hepatol; 2020 Sep; 35(9):1555-1561. PubMed ID: 32167186
[TBL] [Abstract][Full Text] [Related]
13. Comparative effectiveness and cost-effectiveness of screening colonoscopy vs. sigmoidoscopy and alternative strategies.
Sharaf RN; Ladabaum U
Am J Gastroenterol; 2013 Jan; 108(1):120-32. PubMed ID: 23247579
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of computed tomographic colonography screening for colorectal cancer in the medicare population.
Knudsen AB; Lansdorp-Vogelaar I; Rutter CM; Savarino JE; van Ballegooijen M; Kuntz KM; Zauber AG
J Natl Cancer Inst; 2010 Aug; 102(16):1238-52. PubMed ID: 20664028
[TBL] [Abstract][Full Text] [Related]
15. Clinical and Economic Impact of Tailoring Screening to Predicted Colorectal Cancer Risk: A Decision Analytic Modeling Study.
Ladabaum U; Mannalithara A; Mitani A; Desai M
Cancer Epidemiol Biomarkers Prev; 2020 Feb; 29(2):318-328. PubMed ID: 31796524
[TBL] [Abstract][Full Text] [Related]
16. As tests evolve and costs of cancer care rise: reappraising stool-based screening for colorectal neoplasia.
Parekh M; Fendrick AM; Ladabaum U
Aliment Pharmacol Ther; 2008 Apr; 27(8):697-712. PubMed ID: 18248653
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness simulation and analysis of colorectal cancer screening in Hong Kong Chinese population: comparison amongst colonoscopy, guaiac and immunologic fecal occult blood testing.
Wong CK; Lam CL; Wan YF; Fong DY
BMC Cancer; 2015 Oct; 15():705. PubMed ID: 26471036
[TBL] [Abstract][Full Text] [Related]
18. Fecal occult blood testing when colonoscopy capacity is limited.
Wilschut JA; Habbema JD; van Leerdam ME; Hol L; Lansdorp-Vogelaar I; Kuipers EJ; van Ballegooijen M
J Natl Cancer Inst; 2011 Dec; 103(23):1741-51. PubMed ID: 22076285
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness, benefit harm and cost effectiveness of colorectal cancer screening in Austria.
Jahn B; Sroczynski G; Bundo M; Mühlberger N; Puntscher S; Todorovic J; Rochau U; Oberaigner W; Koffijberg H; Fischer T; Schiller-Fruehwirth I; Öfner D; Renner F; Jonas M; Hackl M; Ferlitsch M; Siebert U;
BMC Gastroenterol; 2019 Dec; 19(1):209. PubMed ID: 31805871
[TBL] [Abstract][Full Text] [Related]
20. Screening for Colorectal Cancer With Fecal Immunochemical Testing With and Without Postpolypectomy Surveillance Colonoscopy: A Cost-Effectiveness Analysis.
Greuter MJE; de Klerk CM; Meijer GA; Dekker E; Coupé VMH
Ann Intern Med; 2017 Oct; 167(8):544-554. PubMed ID: 28973514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]